Showing 591-600 of 9358 results for "".
- Industry Responds to COVID-19: UCB, Galderma, Timeless Skin Carehttps://practicaldermatology.com/news/industry-responds-to-covid-19-ucb-galderma-timeless-skin-care/2460354/UCB. UCB is working with the Seattle Structural Genomics Center for Infectious Disease to identify crystal structures of SARS-CoV-2 proteins. In addition to providing funding support to organizations in need during this challenging time, UCB’s research facility in Bedford, Massachusetts, donated sa…
- Nation's Largest Nurses Union to Congress: Ensure Standards for Healthcare Workers to Avoid COVID-19https://practicaldermatology.com/news/nations-largest-nurses-union-to-congress-ensure-standards-for-healthcare-workers-to-avoid-covid-19/2460314/National Nurses United, the largest union of registered nurses, is calling on Congress to mandate that the Occupational Safety and Health Administration promulgate an emergency temporary standard for health care workers in the third COVID-19 stimulus package currently being negotiated. The standa…
- Foamix’s Rosacea Candidate Shows Promise in Phase 3 Studieshttps://practicaldermatology.com/news/foamixs-rosacea-candidate-shows-promise-in-phase-3-studies-1/2460286/Foamix Pharmaceuticals Ltd.’s FMX103 1.5% Topical Minocycline Foam for rosacea performed well in an integrated efficacy analysis of two pivotal Phase 3 clinical trials presented at the 17th Annual South Beach Symposium in Dermatology in Miami, Florida. The U.S. Food and Drug Administration (FDA) a…
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin diseases and aesthetic conditions. DMT310 is first topicall…
- Gillette Skin Guard Reduces Razor Bumps by 60%https://practicaldermatology.com/news/gillette-skin-guard-reduces-razor-bumps-by-60/2460065/Gillette’s recently launched SkinGuard razor is helping men who are susceptible to razor bumps, also known as Pseudofolliculitis barbae or PFB, new research shows. Results from a recent clinical study from Wake Forest University revealed that the incidence of men’s razor bumps was reduced on ave…
- FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCChttps://practicaldermatology.com/news/fda-approves-regenerons-libtayo-first-treatment-for-metastatic-or-locally-advanced-scc/2457589/Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is t…
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity. JWP wi…
- Spironolactone May Be an Alternative to Antibiotics in Female Acnehttps://practicaldermatology.com/news/spironolactone-may-be-an-alternative-to-antibiotics-in-female-acne/2457738/The diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women’s acne, report researchers from the Perelman School of Medicine at the University of Pennsylvania. The study, published in the Journal of Drugs and Dermatology, found patients who were originally pr…
- Smart Hairbrush and Overachieving Mirrors Make Waves at CES 2017https://practicaldermatology.com/news/smart-hairbrush-and-overachieving-mirrors-make-waves-at-ces-2017/2458328/Beauty is getting a whole lot smarter, and more and more companies are getting in on the game. These are among the main takeaways from the BeautyTech Summit at the annual Consumer Electronics Show (CES), taking place in Las Vegas from Jan. 5-8, 2017. This is the be-all, end-all trade show for tech…
- Research Elucidates Skin Phenotype of Pediatric Eczemahttps://practicaldermatology.com/news/research-elucidates-skin-phenotype-of-pediatric-eczema/2458426/Pediatric atopic dermatitis (AD) in infants looks a lot different than adult AD, suggesting the need for alternative, and possibly more aggressive, treatment strategies in children. The study, led by researchers at the Icahn School of Medicine at Mount Sinai in New York City and Northwestern Unive…